Gilead Sciences

A→Z catalog of Gilead

A

• Atripla — Efavirenz + emtricitabine + tenofovir DF — HIV — 1 tab QHS.

• AmBisome — Liposomal amphotericin B — Invasive fungal infections — 3–5 mg/kg IV daily.

• Adenovirus antivirals (cidofovir legacy, see Cidofovir).

B

• Biktarvy — Bictegravir + emtricitabine + tenofovir alafenamide (TAF) — HIV — 1 tab QD.

• **Bexsero (co-market some regions)*.

• Buprenorphine/naloxone generics (indirect access).

C

• Complera / Eviplera — Rilpivirine + emtricitabine + TDF — HIV — 1 tab QD.

• **Covifor (India brand, remdesivir)*.

• Cymara (oncology generics in dev).

• Cidofovir (Vistide) — Cidofovir — CMV retinitis in AIDS — 5 mg/kg IV q1–2w with probenecid.

D

• Descovy — Emtricitabine + TAF — HIV treatment + PrEP — 200/25 mg QD.

• Descovy for PrEP — same combo, PrEP indication.

• Descovy + other agents in combos (Genvoya, Odefsey, Biktarvy).

E

• Emtriva — Emtricitabine — HIV, HBV — 200 mg QD.

• Epclusa — Sofosbuvir + velpatasvir — HCV pan-genotypic — 400/100 mg QD ×12w.

• Eviplera — see C.

F

• Fendrix (co-market HBV vaccine EU).

• Foscarnet (Foscavir, licensed in some markets) — Foscarnet sodium — CMV retinitis, acyclovir-resistant HSV — IV 60 mg/kg q8h.

• Fostemsavir (Rukobia) — Fostemsavir — Multidrug-resistant HIV — 600 mg BID.

G

• Genvoya — Elvitegravir + cobicistat + emtricitabine + TAF — HIV — 1 tab QD with food.

• Gilead Access branded generics (many HIV/TDF combos in LMICs).

H

• Harvoni — Ledipasvir + sofosbuvir — HCV GT1,4,5,6 — 90/400 mg QD ×12w.

• Hepsera (older) — Adefovir dipivoxil — HBV — 10 mg QD.

• Hepatitis B franchise (Vemlidy, Viread, Hepsera, Emtriva).

I

• Idelalisib (Zydelig) — Idelalisib — CLL, FL, SLL — 150 mg BID.

• Islatravir (development terminated with Merck, not marketed).

• Influenza antivirals (partnerships).

J

• Jyseleca (Filgotinib, in EU/Japan via Galapagos/Gilead) — Filgotinib — RA, IBD — 200 mg QD.

K

• Kite Pharma portfolio (cell therapies):

  • Yescarta — Axicabtagene ciloleucel — R/R DLBCL, FL, MCL, LBCL — IV one-time CAR-T infusion.

  • Tecartus — Brexucabtagene autoleucel — MCL, ALL.

  • Carvykti co-dev competitor (Janssen/BMS).

L

• Letairis — Ambrisentan — PAH — 5–10 mg QD.

• Ledipasvir/sofosbuvir (Harvoni) — see H.

• Lenacapavir (Sunlenca) — Lenacapavir — Multidrug-resistant HIV (capsid inhibitor) — 927 mg SC q6m (after loading).

M

• Macugen (pegaptanib; legacy, ophthalmic anti-VEGF).

• Mavyret (AbbVie, competitor not Gilead).

• Mycograb/AmBisome line — antifungals.

N

• Nexletol/Nexlizet (not Gilead; Esperion).

• Non-branded ARV access (Tenofovir, Emtricitabine, Lamivudine combos).

O

• Odefsey — Rilpivirine + emtricitabine + TAF — HIV — 1 tab QD.

• Oseltamivir (Tamiflu; legacy Roche, not Gilead).

P

• Prezcobix (J&J; not Gilead).

• PrEP franchise — Truvada, Descovy.

Q

• Quad (former name of Genvoya).

R

• Remdesivir (Veklury) — Remdesivir — COVID-19 — 200 mg IV Day 1, then 100 mg IV daily ×5–10d.

• Rukobia — Fostemsavir — see F.

• Ranexa (ranolazine, divested legacy).

S

• Sovaldi — Sofosbuvir — HCV GT1–4 (backbone) — 400 mg QD.

• Stribild — Elvitegravir + cobicistat + emtricitabine + TDF — HIV — 1 tab QD.

• Sunlenca — Lenacapavir — see L.

• Symtuza (J&J; not Gilead).

T

• Tamiflu (co-dev with Roche, Gilead retains royalties).

• Truvada — Emtricitabine + TDF — HIV treatment, PrEP — 200/300 mg QD.

• Trodelvy — Sacituzumab govitecan — TNBC, urothelial, HR+ breast cancer — 10 mg/kg IV Days 1 & 8 q21d.

• Tybost — Cobicistat — CYP3A booster — 150 mg QD with combo.

• TDF (Viread) — Tenofovir disoproxil fumarate — HIV, HBV — 300 mg QD.

• TAF (Vemlidy) — Tenofovir alafenamide — HBV — 25 mg QD.

U

• Umbrella access ARV programs — generics licensing portfolio.

V

• Vemlidy — TAF — HBV.

• Viread — TDF — HIV, HBV.

• Vistide — Cidofovir — CMV retinitis.

• Veklury — Remdesivir — see R.

• Volibris (EU/JP, same as Letairis) — Ambrisentan.

• Valcyte (Roche/Genentech drug, not Gilead).

Y

• Yescarta — see K.

Z

• Zydelig — Idelalisib — see I.